Watch WGS. Know when insiders buy.
One email the day a filing lands. Free.
WGS
GeneDx Holdings Corp.
68.94
+0.20 +0.29%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
44
WATCH · insiders 25, shorts 62
Insiders, 90 days
−$1.8M
net selling · 0 buys, 13 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.1BP/E —DIV YIELD —FCF YIELD -3.69%REV TTM $454.4M +25.4%NET INCOME −$106.4M −7664.5%NET DEBT $39.7M52W 34.51 – 167.51SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $114.4M | +11.4% | 68.4% | −$17.5M | −$17.7M | −264.1% | -0.60 | −$29M | $10.1M | −$39.1M | Aug 3 |
| Q1 2026 · Mar 31 | $102.3M | +17.4% | 66.7% | −$57.5M | −$63.3M | — | -2.16 | −$32.4M | $6.5M | −$38.9M | May 4 |
| Q4 2025 · Dec 31derived | $121M | +26.5% | 69.6% | −$14.2M | −$17.7M | −424.9% | -0.61 | −$3.1M | $4.3M | −$7.4M | Feb 23 |
| Q3 2025 · Sep 30 | $116.7M | +51.9% | 72.4% | −$3.3M | −$7.6M | — | -0.27 | $15.8M | $6.2M | $9.6M | Oct 28 |
| Q2 2025 · Jun 30 | $102.7M | +45.6% | 69.0% | $9M | $10.8M | — | 0.36 | $10.4M | $2.4M | $8.1M | Aug 3 |
| Q1 2025 · Mar 31 | $87.1M | +39.6% | 67.1% | −$4.6M | −$6.5M | — | -0.23 | $10.2M | $6.1M | $4.1M | May 4 |
| Q4 2024 · Dec 31derived | $95.6M | +66.6% | 69.2% | $8.8M | $5.4M | — | 0.23 | −$3.2M | $3M | −$6.2M | Feb 23 |
| Q3 2024 · Sep 30 | $76.9M | +44.2% | 62.2% | −$7.8M | −$8.3M | — | -0.31 | −$4.4M | $646K | −$5M | Oct 28 |
| Q2 2024 · Jun 30 | $70.5M | — | 60.9% | −$10.6M | −$29.2M | — | -1.10 | −$4.5M | $1.4M | −$5.9M | Jul 29 |
| Q1 2024 · Mar 31 | $62.4M | — | 59.9% | −$13.7M | −$20.2M | — | -0.78 | −$16.4M | $443K | −$16.9M | Apr 30 |
| Q4 2023 · Dec 31derived | $57.4M | — | 53.6% | −$25.6M | −$25.8M | — | -0.92 | −$29.9M | $2.4M | −$32.2M | Feb 23 |
| Q3 2023 · Sep 30 | $53.3M | — | 47.4% | −$43M | −$42.3M | — | -1.64 | −$41.2M | $112K | −$41.3M | Oct 29 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $427.5M | 69.7% | −$13.1M | −$21M | -4.9% | -0.73 | $33.3M | $19M | $14.3M | — | — |
| FY2024 · to Dec 31 | $305.4M | 63.6% | −$23.2M | −$52.3M | -17.1% | -1.94 | −$28.5M | $5.5M | −$34M | — | — |
| FY2023 · to Dec 31 | $202.6M | 44.4% | −$180.6M | −$175.8M | -86.8% | -7.23 | −$180.1M | $5.3M | −$185.4M | — | — |
| FY2022 · to Dec 31 | $234.7M | -11.4% | −$667.7M | −$549M | -233.9% | -53.63 | −$319.2M | $7.2M | −$326.3M | — | — |
| FY2021 · to Dec 31 | $212.2M | -7.8% | −$446.1M | −$245.4M | -115.6% | -2.27 | −$190.4M | $9.4M | −$199.8M | — | — |
| FY2020 · to Dec 31 | $179.3M | 2.2% | −$242M | −$241.3M | -134.6% | -47036.00 | −$93.1M | $24.1M | −$117.2M | — | — |
Every number comes from GeneDx Holdings Corp.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.